A possible pathophysiological role of tyrosine hydroxylase in Parkinson’s disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer

[1]  A. Nakashima.  Proteasomal degradation of tyrosine hydroxylase and neurodegeneration , 2012, Journal of neurochemistry.

[2]  B. Habecker,et al.  gp130 cytokines stimulate proteasomal degradation of tyrosine hydroxylase via extracellular signal regulated kinases 1 and 2 , 2012, Journal of neurochemistry.

[3]  K. Rayevsky,et al.  Modeling of presymptomatic and symptomatic stages of parkinsonism in mice , 2011, Neuroscience.

[4]  J. Hardy,et al.  Milestones in PD genetics , 2011, Movement disorders : official journal of the Movement Disorder Society.

[5]  N. Hayashi,et al.  Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers proteasomal digestion of the enzyme. , 2011, Biochemical and biophysical research communications.

[6]  S. Cragg,et al.  α-Synuclein and dopamine at the crossroads of Parkinson's disease , 2010, Trends in Neurosciences.

[7]  L. Bubacco,et al.  Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. , 2010, Biochimica et biophysica acta.

[8]  M. Goldberg,et al.  Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.

[9]  M. Palkovits,et al.  Catecholaminergic systems in stress: structural and molecular genetic approaches. , 2009, Physiological reviews.

[10]  F. Dominici,et al.  Angiotensin‐(1–7) through AT2 receptors mediates tyrosine hydroxylase degradation via the ubiquitin–proteasome pathway , 2009, Journal of neurochemistry.

[11]  T. Nagatsu.  The catecholamine system in health and disease —Relation to tyrosine 3-monooxygenase and other catecholamine-synthesizing enzymes— , 2007, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[12]  D. Lynch,et al.  Cytosolic Catechols Inhibit α-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates , 2006, The Journal of Neuroscience.

[13]  M. Sawada,et al.  Cellular and Molecular Mechanisms of Parkinson’s Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines , 2006, Cellular and Molecular Neurobiology.

[14]  P. Dickson,et al.  Differential Regulation of the Human Tyrosine Hydroxylase Isoforms via Hierarchical Phosphorylation* , 2006, Journal of Biological Chemistry.

[15]  C. Olanow,et al.  Proteasomal dysfunction in sporadic Parkinson's disease , 2006, Neurology.

[16]  Kazuto Kobayashi,et al.  Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. , 2005, Biochemical and biophysical research communications.

[17]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[18]  M. Sawada,et al.  Inflammatory process in Parkinson's disease: role for cytokines. , 2005, Current pharmaceutical design.

[19]  David W. Miller,et al.  Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines , 2003, Journal of neurochemistry.

[20]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[21]  T. Flatmark,et al.  Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. , 2002, European journal of biochemistry.

[22]  N. Nomura,et al.  Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. , 1999, Biochemistry.

[23]  D. Goldstein,et al.  Sympathetic cardioneuropathy in dysautonomias. , 1997, Advances in pharmacology.

[24]  H. Ichinose,et al.  Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys. , 1995, Neurodegeneration.

[25]  H. Ichinose,et al.  Increased heterogeneity of tyrosine hydroxylase in humans. , 1993, Biochemical and biophysical research communications.

[26]  Toshiharu Nagats,et al.  Genes for human catecholamine-synthesizing enzymes , 1991, Neuroscience Research.

[27]  R. Teradaira,et al.  Sandwich enzyme immunoassay of dopamine-β-hydroxylase in cerebrospinal fluid from control and parkinsonian patients , 1988, Neurochemistry International.

[28]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[29]  Y. Kurosawa,et al.  Structure of the human tyrosine hydroxylase gene: alternative splicing from a single gene accounts for generation of four mRNA types. , 1988, Journal of biochemistry.

[30]  P. Riederer,et al.  Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents , 1988, Journal of neurochemistry.

[31]  J. Kelsoe,et al.  Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5' alternative splice sites responsible for multiple mRNAs. , 1987, Biochemistry.

[32]  Y. Kurosawa,et al.  Isolation of a novel cDNA clone for human tyrosine hydroxylase: alternative RNA splicing produces four kinds of mRNA from a single gene. , 1987, Biochemical and biophysical research communications.

[33]  J. Mallet,et al.  A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics , 1987, Nature.

[34]  T. Nagatsu.  Dopamine-β-hydroxylase in blood and cerebrospinal fluid , 1977 .

[35]  T. Nagatsu,et al.  Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[36]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[37]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[38]  Vincenzo Bonifati,et al.  Autosomal recessive parkinsonism. , 2012, Parkinsonism & related disorders.

[39]  R. Uitti,et al.  Autosomal dominant Parkinson's disease. , 2012, Parkinsonism & related disorders.

[40]  A. Brice,et al.  Role of mendelian genes in "sporadic" Parkinson's disease. , 2012, Parkinsonism & related disorders.

[41]  N. Hattori.  Autosomal dominant parkinsonism: its etiologies and differential diagnoses. , 2012, Parkinsonism & related disorders.

[42]  V. Bonifati.  1.1.2 AUTOSOMAL RECESSIVE PARKINSONISM , 2012 .

[43]  P. Mcgeer,et al.  The Role of Anti-Inflammatory Agents in Parkinson’s Disease , 2007, CNS drugs.

[44]  N. Gao,et al.  Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. , 2007, Neuroscience bulletin.

[45]  M. Sawada,et al.  Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. , 2007, Journal of neural transmission. Supplementum.

[46]  N. Hattori,et al.  Progress in familial Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[47]  H. Ehringer,et al.  Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.

[48]  K. Jellinger,et al.  Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain , 2005, Journal of Neural Transmission.

[49]  H. Mies.  Untersuchungen über die „vegetative” Umstimmung im Training , 2005, Acta Neurovegetativa.

[50]  M. Zigmond,et al.  A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  K. Lesch,et al.  Neural degeneration in Parkinson's disease. , 2001, Advances in neurology.

[52]  P. Riederer,et al.  The L-DOPA story - an early Japanese contribution , 2000 .

[53]  H. Ichinose,et al.  Cytokines in Parkinson’s Disease , 2000 .

[54]  T. Nagatsu,et al.  Catecholamine Synthesis and Release , 1997 .

[55]  T Nagatsu,et al.  Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. , 1995, Essays in biochemistry.

[56]  K. Lange,et al.  Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[57]  T. Nagatsu,et al.  Genes for human catecholamine-synthesizing enzymes. , 1991, Neuroscience research.